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Introduction
Aerosol antibiotics administration offers the theoretical
advantages of achieving high drug concentrations at the
infection site and low systemic absorption.
Objectives
Comparing the microbiological outcome of inhaled cef-
tazidime amikacin versus inhaled colistin as adjunctives
to conventional iv antibiotics in treating gram negative
VAP.
Methods
This prospective randomized controlled study was car-
ried out on 60 mechanically ventilated patients with
gram negative VAP.
Inclusion criteria: Adult mechanically ventilated
patients diagnosed to have Gram negative VAP con-
firmed:· Radiologically (new chest x- ray infiltrate).
· Microbiologically (positive culture from aspirate of
endo- tracheal tube (ETT).
· Clinically (fever, leukocytosis and increased bronchial
secretion). CPIS scoring >6.
Exclusion criteria: · Severe renal impairment,
The patients included in the study were equally rando-
mized to enter one of 3 groups; group A, group B or
group C.
· Group (A) 20 patients: nebulized ceftazidime (15 mg.
kg. 3 h) plus nebulized amikacin (25 mg·kg·d) in addi-
tion to conventional IV antibiotics.
· Group (B) 20 patients: nebulized Colistin (1million
IU every 8h) in addition to
conventional IV antibiotics.
· Group (C) 20 patients: conventional IV antibiotics.
In all groups A,B and C, treatment was continued for
five days followed by ETT aspirate.
Interpretation of culture results:
Clearance: no growth. Resistance: persistent pathogen.
Super infection: eradication of previous pathogen with
developing of another pathogen. Resistance and super
infection: persistent responsible pathogen with develop-
ing of another pathogen.
Results
The clearance of organism was (75% vs. 80% vs. 50%),
resistance was (5% vs. 5% vs. 20%), superinfection was (0%
vs. 10% vs. 15%), while combined resistance and super
infection was (20% vs. 5% vs. 15%) in group A vs. B vs. C
respectively.
Comparing group B vs. C: a significantly greater
clearance (80% vs. 50%, p 0.047) while no significant
difference regarding resistance (5% vs. 20%, p 0.151),
superinfection (2% vs. 15%, p 0.633), combined resis-
tance and super infection (5% vs. 15%, p 0.292) in
group B vs. C respectively.
Comparing group A vs. C: no significant difference in
clearance (75% vs.50%, p 0.102), resistance (5% vs. 20%,
p 0.151), superinfection (0% vs. 15%, p 0.072), combined
resistance and super infection (20% vs. 15%, p 0.667) in
group A vs. C respectively.
Comparing group A vs. B: no significant difference in
clearance (75% vs.80%, p 0.705), resistance (5% vs. 5%, p
1.0), superinfection (0% vs. 10%, p 0.147), combined
resistance and super infection (20% vs. 5%, p 0.151) in
group A vs. B respectively.
Conclusions
The addition of Inhaled Colistin showed a significantly
better organism clearance after 5 days compared to
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inhaled Ceftazidime and Amikacin and compared to iv
antibiotics without additional inhaled antibiotics, in
treating gram negative VAP.
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